ATE406907T1 - Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4 - Google Patents

Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Info

Publication number
ATE406907T1
ATE406907T1 AT99958695T AT99958695T ATE406907T1 AT E406907 T1 ATE406907 T1 AT E406907T1 AT 99958695 T AT99958695 T AT 99958695T AT 99958695 T AT99958695 T AT 99958695T AT E406907 T1 ATE406907 T1 AT E406907T1
Authority
AT
Austria
Prior art keywords
trk receptor
angiogenesis
methods
present
receptor ligand
Prior art date
Application number
AT99958695T
Other languages
English (en)
Inventor
Barbara Hempstead
Rosemary Kraemer
Shahin Rafii
Phi Wiegn
Michael Donovan
Original Assignee
Cornell Res Foundation Inc
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Childrens Medical Center filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE406907T1 publication Critical patent/ATE406907T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
AT99958695T 1998-10-28 1999-10-28 Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4 ATE406907T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10592898P 1998-10-28 1998-10-28
US11999499P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
ATE406907T1 true ATE406907T1 (de) 2008-09-15

Family

ID=26803105

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958695T ATE406907T1 (de) 1998-10-28 1999-10-28 Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Country Status (7)

Country Link
US (2) US7723293B2 (de)
EP (1) EP1126869B1 (de)
AT (1) ATE406907T1 (de)
CA (1) CA2348835A1 (de)
DE (1) DE69939484D1 (de)
ES (1) ES2316194T3 (de)
WO (1) WO2000024415A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028424A1 (es) * 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
IL153375A0 (en) 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
US7507799B2 (en) 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
AU2007219714A1 (en) * 2006-02-28 2007-09-07 Regenertech Pty Limited Tissue regeneration II
US9179111B2 (en) * 2013-04-26 2015-11-03 Event Show Productions, Inc. Portable handheld video monitors adapted for use in theatrical performances

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4119618A (en) 1976-04-28 1978-10-10 Said Sami I Vasoactive polypeptide and method of preparation from neural tissue
US5401832A (en) 1984-12-24 1995-03-28 Merck & Co., Inc. Brain derived and recombinant acidic fibroblast growth factor
EP0399816B1 (de) 1989-05-24 1995-12-20 Merck & Co. Inc. Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5235043A (en) 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5811396A (en) * 1991-03-14 1998-09-22 The United States Of America As Represented By The Department Of Health And Human Services TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5733871A (en) 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
US5488099A (en) 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
US5684136A (en) 1992-05-18 1997-11-04 Genentech, Inc. Chimeric hepatocyte growth factor (HGF) ligand variants
EP0663007A1 (de) 1992-09-29 1995-07-19 The President And Fellows Of Harvard College Trophischer faktor mit ion-kanal-induzierender aktivität in neuronalen zellen
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
EP0699204B1 (de) * 1993-05-28 1998-04-15 Cephalon, Inc. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO1996033731A1 (en) * 1995-04-26 1996-10-31 Regeneron Pharmaceuticals, Inc. Methods of using neurotrophic factors to enhance neuronal grafts
DE19522476A1 (de) * 1995-06-21 1997-01-02 Bayer Ag Fluor enthaltende Dispergierhilfsmittel für wäßrige Lacke
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
KR100514277B1 (ko) * 1996-09-13 2005-09-13 유겐가이샤 사이센딴이가꾸겡꾸쇼 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
CA2278621A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
JP2001524828A (ja) 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質
AU8763898A (en) 1997-07-31 1999-02-22 St. Elizabeth's Medical Center Of Boston, Inc. Method for the treatment of grafts
EP1027075A1 (de) 1997-10-27 2000-08-16 Merck & Co., Inc. Gentherapie zur stimulierung der angiogenese
WO1999026480A1 (en) 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
JP2002502885A (ja) 1998-02-11 2002-01-29 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ
AU757789B2 (en) 1998-03-27 2003-03-06 Ribozyme Pharmaceuticals, Inc. Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury

Also Published As

Publication number Publication date
WO2000024415A2 (en) 2000-05-04
US7723293B2 (en) 2010-05-25
ES2316194T3 (es) 2009-04-01
US8853163B2 (en) 2014-10-07
EP1126869B1 (de) 2008-09-03
DE69939484D1 (de) 2008-10-16
US20070110735A1 (en) 2007-05-17
WO2000024415A9 (en) 2000-11-30
US20100227823A1 (en) 2010-09-09
EP1126869A2 (de) 2001-08-29
CA2348835A1 (en) 2000-05-04
WO2000024415A3 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
Xu et al. Acute effects of whole-body exposure to static magnetic fields and 50-Hz electromagnetic fields on muscle microcirculation in anesthetized mice
DE69631605D1 (de) Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
DE69633411D1 (de) Vorrichtung zur umgehung von arteriellen verengungen und/oder zur ausführung anderer transvaskularer eingriffe
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
NO903059D0 (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
DE60035163D1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
DE69637587D1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE69635204D1 (de) Vorrichtung und Verfahren zur Erzeugung vertrauter, architekturspezifischer, kompilierter Versionen von architekturneutralen Programmen
DE69731385D1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2071778T3 (es) Equivalentes de tejidos vivos.
EP0180596A4 (de) Verfahren zur verhütung der bindung des willebrand-faktors an menschliche blutplättchen und zur stimulierung der interaktion der plättchen mit gefässwänden.
DE3886254D1 (de) Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat.
DE59910994D1 (de) Vorrichtung zur behandlung von körpergewebe mittels ultraschall
ATE318326T1 (de) Verwendung von in neuriten lokalisierten mrnas zur medizinischen diagnose und therapie
ATE322016T1 (de) Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse
DE69939484D1 (de) Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
Fournier et al. Somatotopy in the segmental innervation of the cat diaphragm
DE69326018D1 (de) Methoden zur bestimmung der blutplaettchenfunktion
ATE274053T1 (de) Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
ATE283478T1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
DE68920477D1 (de) Verfahren zur Diagnose von Tumoren.
Mark et al. The release of immunoreactive neuropeptide Y in the spinal cord of the anaesthetized rat and cat
Upchurch Jr et al. Changes in the amplitude of cyclic load biphasically modulate endothelial cell DNA synthesis and division

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties